Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. - Wikidata - awgldk - TriplyDB

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum.

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum.

http://www.wikidata.org/entity/Q39362892

about

Vaccines against malaria Advances and challenges in malaria vaccine development Immune mechanisms in malaria: new insights in vaccine development Vaccines for preventing malaria (blood-stage)Human malarial disease: a consequence of inflammatory cytokine release That Was Then But This Is Now: Malaria Research in the Time of an Eradication Agenda Intermittent preventive treatment for malaria in infants Acquired immunity to malaria Promising functional readouts of immunity in a blood-stage malaria vaccine trial Interferon-γ: The Jekyll and Hyde of Malaria Profiling the host response to malaria vaccination and malaria challenge IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection CD19(+) B cells confer protection against experimental cerebral malaria in semi-immune rodent model A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs P. falciparum enhances HIV replication in an experimental malaria challenge system Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1 Nitric oxide production and mononuclear cell nitric oxide synthase activity in malaria-tolerant Papuan adults Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.Modelling the epidemiological impact of intermittent preventive treatment against malaria in infants.Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.Distinct roles for FOXP3 and FOXP3 CD4 T cells in regulating cellular immunity to uncomplicated and severe Plasmodium falciparum malaria Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children.Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria.Low density parasitaemia, red blood cell polymorphisms and Plasmodium falciparum specific immune responses in a low endemic area in northern Tanzania Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies.Cross-species malaria immunity induced by chemically attenuated parasites.Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.The contribution of vaccination to global health: past, present and future.Plasmacytoid dendritic cells appear inactive during sub-microscopic Plasmodium falciparum blood-stage infection, yet retain their ability to respond to TLR stimulation Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria.Differential cellular recognition of antigens during acute Plasmodium falciparum and Plasmodium vivax malaria.Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.Protection from experimental cerebral malaria with a single dose of radiation-attenuated, blood-stage Plasmodium berghei parasites.Age-related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein 1 Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice.Causes of variation in malaria infection dynamics: insights from theory and data.Intermittent preventive treatment with sulfadoxine-pyrimethamine does not modify plasma cytokines and chemokines or intracellular cytokine responses to Plasmodium falciparum in Mozambican children.Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic Plasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP).Severe malarial anemia: innate immunity and pathogenesis.

P2860

Q17485685-57A5D954-7AA2-4575-BFFD-3BC455991D44 Q21032463-B63EF0F4-796F-4ED4-BADF-2FC91E6B987A Q21032484-43514AF2-CEBF-41F2-9101-D03C3EE9BF6F Q21032518-41D18672-7E6A-488D-ABAD-2ED61C0CEEC5 Q21034098-478715ED-B105-4789-97F4-1EDCB905C9C8 Q22061808-6F168486-954C-400D-94E4-D9B0014EC033 Q24188349-51D35580-C8D1-4E17-8D5F-30355B8C0272 Q24651173-3467056C-ED11-47D8-99F2-9605906269C7 Q24814446-C76D2956-81B8-458E-9A12-B4AF33067A70 Q26782988-321FE82B-77C5-4786-934C-FD5E51B6254A Q26800494-5000EA84-C5FF-4EC2-8073-FC60573759E9 Q27317276-FA18213F-B993-430D-909F-E9D8FEB11772 Q27318165-DF7402C9-56D9-49A2-86BE-CCD10C7A9ADE Q28476638-02C883CD-C87A-48EC-9CF8-9644A0C677F4 Q28727971-8AFCA93D-22F1-4B39-8D8B-90000DC3F3CF Q28743564-98A103F6-9A14-4C70-AB98-716E27EF5167 Q31147217-C7E680A7-95C5-4212-A912-60A687F04DE2 Q33317265-3B0B5426-D676-4A4A-BC62-D8569DB4E98D Q33351939-B7D5B254-0A27-4A23-8502-25DB12CB4CD4 Q33415066-07367E79-713B-487F-91E2-FA8DB7D06634 Q33426367-36D14F10-8069-4739-93FB-940166D79008 Q33430011-451C9569-5422-4F78-A82F-CB71F954E5BE Q33434467-21B51FF9-F4AF-4111-AAD5-10903E4FD731 Q33449934-0159AE88-25F0-4D52-944D-C97ECA1FF91B Q33492290-CACBD3CF-EDA9-4C0B-AF2A-771EE2896276 Q33570804-1BEC6699-3A79-4BD6-A837-6A22D60B3B68 Q33587443-DBB365EF-CA0E-44C6-96C6-3E580A79F8DC Q33624593-42FB21F6-65DD-4A7B-B57D-1E8B8BB5903A Q33752813-CAFC8E85-CEA4-4F4A-89B4-8600BE462E9D Q33769200-0AEF62F0-3616-4CEF-8017-EDF815D11725 Q33857969-B68783C6-7BC5-4F06-BB96-690A9A2970EB Q33974904-3FBD22C1-BD55-4002-A807-7519FC331607 Q34026083-2FF4D7A0-5874-439D-8000-F8C2736F42BE Q34026347-A97058D3-2218-4C20-9F14-32E92782848D Q34028638-F1148BC2-4D46-4F17-8E7E-91631E6F684E Q34076283-063A8EFF-4AFB-4262-8E3F-10B490F32BB4 Q34142179-DC2FEF6F-FDF7-4C45-A8CD-AA3EA269BD1F Q34189972-59103D45-1316-4B90-AB15-DD99DE5535F5 Q34215916-F9666457-36F5-4EB5-812E-B433D0A783B6 Q34235396-4C2A4692-D4F6-413D-988A-DD8C00599522

P2860

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum.

http://www.wikidata.org/entity/Q39362892

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Immunity to malaria after admi ...... ed with Plasmodium falciparum.

@en

Immunity to malaria after admi ...... ed with Plasmodium falciparum.

@nl

type

label

Immunity to malaria after admi ...... ed with Plasmodium falciparum.

@en

Immunity to malaria after admi ...... ed with Plasmodium falciparum.

@nl

prefLabel

Immunity to malaria after admi ...... ed with Plasmodium falciparum.

@en

Immunity to malaria after admi ...... ed with Plasmodium falciparum.

@nl

P1433

Q39362892-C2AE61F3-D9AC-4A21-9C91-E22C4E0EA51C

P1476

Q39362892-FE99721E-23A0-4243-9819-3AB573370F33

P2093

Q39362892-2FE4A2BA-1BAD-49CD-89D4-8E4B46D6FF36

Q39362892-392B6E6D-156B-46FB-8709-6302D9B2E661

Q39362892-3D25B6DA-A4BE-4BCD-975C-7BDFCAE3630F

Q39362892-4697ACD9-7990-48DC-881A-AC49CB780301

Q39362892-550594A4-D4C7-450B-976E-4D92985B36E1

Q39362892-911A0277-3BC1-4671-A793-300D5688F7E2

Q39362892-94E94CC0-F231-470F-AC5B-069225E99E24

Q39362892-A386A6E4-8865-47C4-BF09-1B619E299473

Q39362892-B0D9879D-25EE-4413-A793-3B172782AF40

Q39362892-D2D07B23-A893-476A-ADE4-7C4DD10AC8C6

P304

Q39362892-AFDB12C8-4E4A-4CF7-BF30-BC6079CA050D

P31

Q39362892-F0ECE8B6-0CE6-437F-BCDC-2A0EA075904A

P356

Q39362892-C0F6E988-BB70-4D46-9289-F6F9DAF095E7

P407

Q39362892-BAEC30F8-E7A5-4263-8023-1A85007F045B

P433

Q39362892-141F4403-A46B-4186-AA08-5585FE7EDDD9

P478

Q39362892-7E6A2C49-E784-4DD8-B6E5-312ADF670A65

P50

Q39362892-14B197D4-9A56-4407-B4ED-1BA5CA0749C0

Q39362892-269143C8-71AE-42E5-BD76-5660335988F1

Q39362892-3AAF619E-EE45-44A1-B720-6D74D9A259DA

Q39362892-6CBD4E25-F471-41E7-A53E-4EEFDBEEF8F0

Q39362892-7DFCF0DE-894F-42EE-9A35-17C9D4657779

P577

Q39362892-F6037545-0157-4E33-82B6-3F17FFBD059F

P698

Q39362892-F516665C-E475-4580-BCDC-ED332CE0B051

P921

Q39362892-42CAE282-4F49-4625-A16F-1D1E233F8D5A

Q39362892-98127DB7-9B7E-4F14-BFC3-B5CD442C7318

P356

S0140-6736(02)09784-2

P1433

P1476

Immunity to malaria after admi ...... ed with Plasmodium falciparum.

@en

P2093

Chakrit Hirunpetcharat

http://www.w3.org/2001/XMLSchema#string

Christine Rzepczyk

http://www.w3.org/2001/XMLSchema#string

David J Pombo

http://www.w3.org/2001/XMLSchema#string

Gregor Lawrence

http://www.w3.org/2001/XMLSchema#string

J Brice Weinberg

http://www.w3.org/2001/XMLSchema#string

Karen Anderson

http://www.w3.org/2001/XMLSchema#string

Laura B Martin

http://www.w3.org/2001/XMLSchema#string

Michelle Bryden

http://www.w3.org/2001/XMLSchema#string

Salenna Elliott

http://www.w3.org/2001/XMLSchema#string

Suzanne Elliott

http://www.w3.org/2001/XMLSchema#string

P304

610-617

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(02)09784-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

9333

http://www.w3.org/2001/XMLSchema#string

P478

360

http://www.w3.org/2001/XMLSchema#string

P50

Michael F. Good

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12241933

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium falciparum